Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. While traditional screenings such as colonoscopy and fecal testing are critical, they often detect cancer after it has already developed. Prometastatic molecular changes, however, can occur much earlier as the tumor microenvironment evolves.

The Colorectal Carcinoma Prometastatic Assay evaluates biomarker patterns of immune dysregulation, prometastatic signaling, and tumor-driven inflammation that drive colorectal cancer progression and metastasis. This assay supports earlier detection, treatment guidance, and recurrence monitoring.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Colorectal Carcinoma Prometastatic Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Early Detection Potential

Identifies prometastatic changes before colorectal tumors fully develop or spread.

Treatment Guidance

Provides immune-molecular insights to support precision therapies, including immunotherapy and targeted therapy.

Recurrence Monitoring

Tracks molecular shifts in patients post-treatment or surgery.

Complementary Testing

Enhances colonoscopy and pathology results with immune-molecular analysis.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Colorectal Carcinoma Prometastatic Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and colorectal tumor progression:

  • Prometastatic proteins (MMPs, VEGF, TGF-β)

  • Immune checkpoint activity (PD-L1, CTLA-4 pathways)

  • Inflammatory cytokines and chemokines (IL-6, IL-8, TNF-α)

  • Tumor microenvironment markers linked to invasion and spread

  • Oxidative stress and metabolic imbalance indicators

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Secure registration via the Persona Biomed portal.

02

Sample Collection

Standard blood draw performed at a certified lab or via mobile phlebotomy.

03

Laboratory Analysis

High-sensitivity molecular assays quantify prometastatic and immune-related biomarkers.

04

Results Delivery

Detailed physician-ready report available in the portal, with AI-powered patient summaries for clarity.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Individuals at high risk for colorectal cancer due to family history or genetic predisposition.

  • Patients with abnormal colonoscopy results or polyps.

  • Individuals undergoing colorectal cancer treatment requiring molecular monitoring.

  • Survivors seeking recurrence risk assessment.

Register Now for Colorectal Carcinoma Prometastatic Assay

Register now for the Colorectal Carcinoma Prometastatic Assay to uncover early molecular signals of colorectal cancer progression and metastasis.

Register now